Geert R. D'haens
Expertise in
4
conditions

Geert R. D'haens

Amsterdam UMC
Amsterdam, NH, NL 
Expertise in
4
conditions
Amsterdam UMC
Amsterdam, NH, NL 

Overview

Geert D'haens practices practicing medicine in Amsterdam, Netherlands.

D'haens is highly rated in 4 conditions, according to our data. Their clinical expertise encompasses Hemorrhagic Proctocolitis, Ulcerative Colitis, Colitis, Viral Gastroenteritis, and Appendectomy.

They are actively involved in clinical research, co-authoring 74 peer reviewed articles and participating in 6 clinical trials.

Locations

Amsterdam UMC
Amsterdam, NH, Netherlands
Other Locations
Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Enrollment Status: Active_not_recruiting
Publish Date: January 27, 2026
Intervention Type: Biological
Study Drug: Vedolizumab
Study Phase: Phase 4
Randomized, Multicenter Study to Investigate the Efficacy of Dashboard Driven Individualized Dosing of Infliximab Compared To Standard Dosing During the Induction in Patients With Acute Severe Ulcerative Colitis
Randomized, Multicenter Study to Investigate the Efficacy of Dashboard Driven Individualized Dosing of Infliximab Compared To Standard Dosing During the Induction in Patients With Acute Severe Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drug: Infliximab
Study Phase: Phase 4
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOw Countries VEdolizumab in CD Study)
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOw Countries VEdolizumab in CD Study)
Enrollment Status: Completed
Publish Date: June 23, 2023
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 4
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II, Randomized, Multi-centre, Double-blind, Parallel-group, Dose-ranging, Exploratory Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 (Mesalazine) Once Daily
A Phase II, Randomized, Multi-centre, Double-blind, Parallel-group, Dose-ranging, Exploratory Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 (Mesalazine) Once Daily
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)
Enrollment Status: Completed
Publish Date: October 08, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 5 Less Clinical Trials

74 Total Publications

Stability of infliximab serum concentrations during long-term frozen storage: a paired biobank study.
Stability of infliximab serum concentrations during long-term frozen storage: a paired biobank study.
Journal: Journal of Crohn's & colitis
Published: July 31, 2026

Frequently Asked Questions about Geert R. D'haens

Is Geert R. D'haens a top-rated expert for Hemorrhagic Proctocolitis?

MediFind is an objective health platform that identifies experts based on real-world data. Geert R. D'haens is classified as an Distinguished expert for Hemorrhagic Proctocolitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Geert R. D'haens participate in research or clinical trials?

Yes. Geert R. D'haens has published 74 articles and abstracts on conditions like Hemorrhagic Proctocolitis. You can view a list of Geert R. D'haens's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find D'haens's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile